Your browser doesn't support javascript.
loading
Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma.
Mondello, Patrizia; Tadros, Saber; Teater, Matt; Fontan, Lorena; Chang, Aaron Y; Jain, Neeraj; Yang, Haopeng; Singh, Shailbala; Ying, Hsia-Yuan; Chu, Chi-Shuen; Ma, Man Chun John; Toska, Eneda; Alig, Stefan; Durant, Matthew; de Stanchina, Elisa; Ghosh, Sreejoyee; Mottok, Anja; Nastoupil, Loretta; Neelapu, Sattva S; Weigert, Oliver; Inghirami, Giorgio; Baselga, José; Younes, Anas; Yee, Cassian; Dogan, Ahmet; Scheinberg, David A; Roeder, Robert G; Melnick, Ari M; Green, Michael R.
Afiliação
  • Mondello P; Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medical College, New York, New York.
  • Tadros S; Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Teater M; Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medical College, New York, New York.
  • Fontan L; Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medical College, New York, New York.
  • Chang AY; Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Jain N; Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Yang H; Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Singh S; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Ying HY; Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medical College, New York, New York.
  • Chu CS; Laboratory of Biochemistry and Molecular Biology, The Rockefeller University, New York, New York.
  • Ma MCJ; Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Toska E; Department of Human Oncology and Pathogenesis, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Alig S; Department of Internal Medicine III, University Hospital of the Ludwig-Maximilians-University Munich, Munich, Germany.
  • Durant M; Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medical College, New York, New York.
  • de Stanchina E; Antitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Ghosh S; Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Mottok A; Institute of Pathology, University of Würzburg and Comprehensive Cancer Center Mainfranken, Würzburg, Germany.
  • Nastoupil L; Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Neelapu SS; Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Weigert O; Department of Internal Medicine III, University Hospital of the Ludwig-Maximilians-University Munich, Munich, Germany.
  • Inghirami G; Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, New York.
  • Baselga J; Laboratory of Biochemistry and Molecular Biology, The Rockefeller University, New York, New York.
  • Younes A; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Yee C; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Dogan A; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Scheinberg DA; Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Roeder RG; Laboratory of Biochemistry and Molecular Biology, The Rockefeller University, New York, New York.
  • Melnick AM; Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medical College, New York, New York. mgreen5@mdanderson.org amm2014@med.cornell.edu.
  • Green MR; Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas. mgreen5@mdanderson.org amm2014@med.cornell.edu.
Cancer Discov ; 10(3): 440-459, 2020 03.
Article em En | MEDLINE | ID: mdl-31915197
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteína de Ligação a CREB / Inibidor de Quinase Dependente de Ciclina p21 / Proteínas Proto-Oncogênicas c-bcl-6 / Histona Desacetilases / Linfoma Tipo de estudo: Screening_studies Limite: Animals / Humans Idioma: En Revista: Cancer Discov Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteína de Ligação a CREB / Inibidor de Quinase Dependente de Ciclina p21 / Proteínas Proto-Oncogênicas c-bcl-6 / Histona Desacetilases / Linfoma Tipo de estudo: Screening_studies Limite: Animals / Humans Idioma: En Revista: Cancer Discov Ano de publicação: 2020 Tipo de documento: Article